A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer

Morgensztern, Daniel; Ready, Neal; L. Johnson, Melissa; Dowlati, Afshin; Choudhury, Noura; P. Carbone, David; Schaefer, Eric; M. Arnold, Susanne; Puri, Sonam; Piotrowska, Zofia; Hegde, Aparna; C. Chiang, Anne; Iams, Wade; Tolcher, Anthony; Nosaki, Kaname; Kozuki, Toshiyuki; Li, Tianhong; Santana-Davila, Rafael; Akamatsu, Hiroaki; Murakami, Haruyasu; Yokouchi, Hiroshi; Wang, Song; Zha, Jiuhong; Li, Rui; R. Robinson, Randy; Hingorani, Pooja; E. Jeng, Edwin; Furqan, Muhammad

doi:10.1158/1078-0432.ccr-24-1547

Public

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer

Shared by NobleBlocks on Sep 17, 2024 • 12:00 AM UTC

Authors:

Daniel Morgensztern

Neal Ready

Melissa L. Johnson

Abstract

Abstract Purpose: Seizure-related homolog protein 6 (SEZ6) is a novel target expressed in small cell lung cancer (SCLC). ABBV-011, a SEZ6-targeted antibody conjugated to calicheamicin, was evaluated in a phase I study (NCT03639194) in patients with relapsed/refractory SCLC. We report initial outcome...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!